Delft speeds up restructuring after poor first half
This article was originally published in Clinica
Following a disappointing half year, Delft Instruments is to accelerate its reorganisation measures, increasing pressure on unprofitable business units. The Dutch company says these will either be integrated into other divisions, reorganised or sold within the foreseeable future. It has earmarked between Fl 50 and Fl 60 million ($25-$30 million) for the restructuring.
You may also be interested in...
US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.
Mallinckrodt to pay $1.6bn and place its generics unit in bankruptcy under agreement in principle for US global settlement; six states are not on board, including New York, whose suit is still set to go to trial March 20.
The company has reached a broad opioid settlement agreement in principle under which its specialty generics subsidiaries would file for Chapter 11 bankruptcy and Mallinckrodt's branded business would operate separately.